Peter A. LeWitt

22.3k total citations
200 papers, 8.1k citations indexed

About

Peter A. LeWitt is a scholar working on Neurology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Peter A. LeWitt has authored 200 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Neurology, 40 papers in Cellular and Molecular Neuroscience and 27 papers in Physiology. Recurrent topics in Peter A. LeWitt's work include Parkinson's Disease Mechanisms and Treatments (125 papers), Neurological disorders and treatments (87 papers) and Botulinum Toxin and Related Neurological Disorders (39 papers). Peter A. LeWitt is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (125 papers), Neurological disorders and treatments (87 papers) and Botulinum Toxin and Related Neurological Disorders (39 papers). Peter A. LeWitt collaborates with scholars based in United States, United Kingdom and Canada. Peter A. LeWitt's co-authors include David A. Loeffler, Rajesh Pahwa, Alberto J. Espay, Robert A. Hauser, Stanley Fahn, Richard S. Burns, James R. Connor, Kelly E. Lyons, Paul Juneau and Mei Lü and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and American Journal of Psychiatry.

In The Last Decade

Peter A. LeWitt

196 papers receiving 7.8k citations

Peers

Countries citing papers authored by Peter A. LeWitt

Since Specialization

Citations

This map shows the geographic impact of Peter A. LeWitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. LeWitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. LeWitt more than expected).

Fields of papers citing papers by Peter A. LeWitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter A. LeWitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. LeWitt. The network helps show where Peter A. LeWitt may publish in the future.

Co-authorship network of co-authors of Peter A. LeWitt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter A. LeWitt. A scholar is included among the top collaborators of Peter A. LeWitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter A. LeWitt. Peter A. LeWitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study 2024 ·Movement Disorders ·Peter A. LeWitt, Glenn T. Stebbins, Kenneth Vielsted Christensen, (unknown), (unknown), Mikael S. Thomsen	5
2	IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease 2023 ·JAMA Neurology ·Robert A. Hauser, Alberto J. Espay, Aaron Ellenbogen, Hubert H. Fernandez, Stuart Isaacson, Peter A. LeWitt, William G. Ondo, Rajesh Pahwa, Johannes Schwarz, Fabrizio Stocchi, Leonid Zeitlin, (unknown), Stanley E. Fisher, (unknown), Richard D’Souza	20
3	Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease 2023 ·Journal of Parkinson s Disease ·(unknown), Peter A. LeWitt	5
4	Diagnostic metabolomic profiling of Parkinson's disease biospecimens 2022 ·Neurobiology of Disease ·Peter A. LeWitt, Jia Li, Kuan-Han Wu, Mei Lü	15
5	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials 2021 ·Journal of Parkinson s Disease ·Robert A. Hauser, Nobutaka Hattori, Hubert H. Fernandez, Stuart Isaacson, Hideki Mochizuki, Olivier Rascol, Fabrizio Stocchi, June Li, Akihisa Mori, (unknown), (unknown), Peter A. LeWitt	26
6	A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease 2020 ·Parkinsonism & Related Disorders ·Eric S. Farbman, Cheryl Waters, Peter A. LeWitt, Monika Rudzińska, (unknown), Amanda Lee, Jenny Qian, Charles Oh, Robert A. Hauser	15
7	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations? 2019 ·Journal of Parkinson s Disease ·David A. Loeffler, Jan Aasly, Peter A. LeWitt, Mary P. Coffey	10
8	Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress 2016 ·Frontiers in Aging Neuroscience ·David A. Loeffler, Andrea C. Klaver, Mary P. Coffey, Jan Aasly, Peter A. LeWitt	16
9	Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations 2016 ·International Journal of Neuroscience ·Neil B. Hampson, Karl Kieburtz, Peter A. LeWitt, Mika Leinonen, Martin I. Freed	16
10	Effective Delivery of Apomorphine in the Management of Parkinson Disease 2015 ·Clinical Neuropharmacology ·Roongroj Bhidayasiri, К. Ray Chaudhuri, Peter A. LeWitt, Anne Martin, (unknown), Teus van Laar	42
11	Clinician versus machine: Reliability and responsiveness of motor endpoints in Parkinson's disease 2014 ·Parkinsonism & Related Disorders ·Dustin A. Heldman, Alberto J. Espay, Peter A. LeWitt, Joseph P. Giuffrida	128
12	Reliability of a new scale for essential tremor 2012 ·Movement Disorders ·Rodger J. Elble, Cynthia Comella, Stanley Fahn, Mark Hallett, Joseph Jankovic, Jorge L. Juncos, Peter A. LeWitt, Kelly E. Lyons, William G. Ondo, Rajesh Pahwa, Kapil D. Sethi, Natividad Stover, Daniel Tarsy, Claudia Testa, Ron Tintner, Ray L. Watts, Theresa Zesiewicz	168
13	Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease 2009 ·Journal of Neuroinflammation ·Dianne M. Camp, David A. Loeffler, (unknown), Jade Borneman, Peter A. LeWitt	54
14	Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases 2003 ·Journal of the Neurological Sciences ·Stefan Lorenzl, David S. Albers, Peter A. LeWitt, Jason W. Chirichigno, (unknown), Merit Cudkowicz, M. Flint Beal	130
15	Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial 2002 ·Annals of Neurology ·Ira Shoulson, David Oakes, Stanley Fahn, Anthony E. Lang, J. William Langston, Peter A. LeWitt, C. Warren Olanow, John B. Penney, Caroline M. Tanner, Karl Kieburtz, Alice Rudolph, (unknown)	200
16	A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains 1995 ·Journal of Neurochemistry ·James R. Connor, Brian S. Snyder, Paolo Arosio, David A. Loeffler, Peter A. LeWitt	264
17	Ceruoplasmin Is Increased in Cerebrospinal Fluid in Alzheimerʼs Disease but Not Parkinsonʼs Disease 1994 ·Alzheimer Disease & Associated Disorders ·David A. Loeffler, A. J. DeMaggio, Paul Juneau, Chaim M. Brickman, George A. Mashour, (unknown), Nunzio Pomara, Peter A. LeWitt	63
18	Symptomatic Anti-Parkinsonian Effects of Monoamine Oxidase-B Inhibition: Comparison of Selegiline and Lazabemide 1993 ·Clinical Neuropharmacology ·Peter A. LeWitt, Scott A. Segel, (unknown), M. Anthony Schork	19
19	Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine 1990 ·Clinical Pharmacology & Therapeutics ·(unknown), Richard Berchou, (unknown), Peter A. LeWitt	31
20	Neuropharmacological Intervention with Motor System Aging 1988 ·Annals of the New York Academy of Sciences ·Peter A. LeWitt	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact